



Atty. Dkt. No. 034536-0928

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Gregory PLOWMAN et al.  
Title: DIAGNOSIS AND TREATMENT OF AUR1 AND/OR AUR2 RELATED DISORDERS  
Appl. No.: 10/734,126  
Filing Date: 12/15/2003  
Examiner: Unassigned  
Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/784,332, filed 02/16/2001 which is a division of application Serial No. 09/283,011, filed 03/31/1999, which is a division of application Serial No. 09/012,135, filed 01/22/1995, which is a continuation-in-part of application Serial No. 09/005,268, filed 01/09/1998, which is a continuation-in-part of application Serial No. 08/755,728, filed 11/25/1996. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent applications.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.


The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

April 15, 2004

By



FOLEY & LARDNER LLP


Customer Number: 22428

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Beth A. Burrous  
Attorney for Applicant  
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/734,126
		Filing Date	December 15, 2003
		First Named Inventor	Gregory Plowman
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet <u>1</u> of <u>14</u>		Attorney Docket Number	034536-0928

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	4,343,940		KREIGHBAUM et al.	08-10-1982	
	A2	4,376,110		DAVID et al.	03-08-1983	
	A3	4,447,608		JONES et al.	05-08-1984	
	A4	4,757,072		KABBE et al.	07-12-1988	
	A5	4,945,050		SANFORD et al.	07-31-1990	
	A6	5,217,999		LEVITZKI et al.	06-08-1993	
	A7	5,283,173		FIELDS et al.	02-01-1994	
	A8	5,302,606		SPADA et al.	04-12-1994	
	A9	5,316,553		KAUL et al.	05-31-1994	
	A10	5,330,992		EISSENSTAT et al.	07-19-1994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
X	A11	EP	0 520 722	A1	ICI PLC	12-30-1992		
X	A12	EP	0 566 226	A1	ZENECA LTD	10-20-1993		
X	A13	EP	0 562 734	A1	ZENECA LTD	09-29-1993		
X	A14	WO	91/15495	A1	PFIZER INC.	10-17-1991		
✓	A15	WO	92/14748	A1	AMERICAN CYANAMID COMPANY	09-03-1992		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number		10/734,126
				Filing Date		December 15, 2003
				First Named Inventor		Gregory Plowman
				Group Art Unit		Unassigned
				Examiner Name		Unassigned
Sheet	2	of	14	Attorney Docket Number		034536-0928

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
✓	A16	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL INC.	11-26-1992		
X	A17	WO	92/21660	A1	PFIZER INC.	12-10-1992		
✓	A18	WO	93/09236	A1	BAYLOR COLLEGE OF MEDICINE	05-13-1993		
✓	A19	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
✓	A20	WO	94/14808	A1	FARMITALIA CARLO ERBA S.R.L.	07-07-1994		
✓	A21	WO	94/23039	A1	THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL	10-13-1994		
X	A22	WO	96/34985	A1	PHARMACIA S.P.A.	08-01-1996		
✓	A23	WO	96/22976	A1	SUGEN INC.	11-07-1996		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
✓	A24	ABE et al., "Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR5 Coupled to Insitol Pohosphate/Ca2+ Signal," <u>J. Biol. Chem.</u> , 1992, PP. 13361-13368, Vol. 267, No. 19		
✓	A25	ALBERTS et al., <u>Molecular Biology of the Cell</u> , Second Edition, published 1989, by Garland Publishing (New York), pp. 265-266 (TABLE OF CONTENTS ONLY)		
✓	A26	ALLEN et al., "Modulation of CD4 by suramin," <u>Clin. Exp. Immunol.</u> , 1991, pp. 141-146, Vol. 91		
✓	A27	ALTSCHUL et al., "Basic Local Alignment Search Tool," <u>J. Mol. Biol.</u> , 1990, pp. 403-410, Vol. 215		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/734,126
		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
		<b>Attorney Docket Number</b>	034536-0928
(use as many sheets as necessary)			
Sheet	3	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A28	ANAFI et al., "Tyrophostin-Induced Inhibition of p210 <sup>bcr-abl</sup> Tyrosine Kinase Activity Induces K562 to Differentiate," <u>Blood</u> , 1993, pp. 3524-3529, Vol. 82	
X	A29	BAKER et al., "Induction of acetylcholine receptor clustering by native polystyrene beads," <u>Journal of Cell Science</u> , 1992, pp. 543-555, Vol. 102	
Y	A30	BARKER et al., "In vitro activity of non-glutamate containing quinazoline-based thymidylate synthase inhibitors," <u>Proceedings of the American Association for Cancer Research</u> , 1991, p. 327 at abstract No. 1939, Vol. 32	
Y	A31	BAYER et al., "The Avidin-Biotin Complex in Affinity Cytochemistry," <u>Methods in Enzymology</u> , 1979, pp. 308-319, Vol. 62	
Y	A32	BENOIST et al., "In vivo sequence requirements of the SV40 early promoter region," <u>Nature</u> , 1981, pp. 304-310, Vol. 290	
Y	A33	BERTINO et al., "Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture," <u>Cancer Research</u> , 1979, pp. 293-304, Vol. 39	
X	A34	BIGNER et al., "Structural chromosomal abnormalities in human medulloblastoma," <u>Cancer Genet. Cytogenet.</u> , 1988, pp. 91-101, Vol. 30	
Y	A35	BILDER et al., "Tyrophostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," <u>Am. J. Physiol.</u> , 1991, pp. C721-C730, Vol. 260, Vol. 29	
X	A36	BOCKMUHL et al., <u>Laryngorhinootologie</u> , 1996, pp. 408-414, Vol. 75	
Y	A37	BOLLON et al., "DNA transformation efficiency of various bacterial and yeast host-vector systems," <u>Journal of Clinical Hematology and Oncology</u> , 1980, pp. 39-487, Vol. 10, Nos. 2 & 3	
Y	A38	BOTSTEIN et al., "Making mutations in vitro and putting them back into yeast," <u>Miami Winter Symposia - From Gene to Protein: Translation into Biotechnology</u> , edited by Ahmad et al., 1982, pp. 265-274, Vol. 19, Academic Press	
X	A39	BRINSTER et al., "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs," <u>Proc. Natl. Acad. Sci. USA</u> , 1985, pp. 4438-4442, Vol. 82	
Y	A40	BROACH et al., "The Yeast Plasmid 2μ Circle," <u>Cell</u> , 1982, pp. 203-204, Vol. 28	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/734,126
		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-0928
Sheet	4	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A41	BROACH, <u>The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance</u> , 1981, pp. 445-470, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY	
✓	A42	BRYCKAERT et al., <u>Experimental Cell Research</u> , 1992, pp. 255-261, Vol. 199	
X	A43	BULLOCK et al., <u>Techniques in Immunocytochemistry</u> , Vol. 1 (1982), Vol. 2 (1982), Vol. 3 (1985), Academic Press, Orlando, FL (TABLE OF CONTENTS ONLY)	
✓	A44	BURKE et al., "Arylamides of Hydroxylated Isoquinolines as Protein-Tyrosine Kinase Inhibitors," <u>Bioorganic &amp; Medical Chemistry Letters</u> , 1992, pp. 1771-1774, Vol. 2, No. 12	
✓	A45	BURKE et al., "Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56 <sup>lck</sup> 1," <u>Journal of Medicinal Chemistry</u> , 1993, pp. 425-432, Vol. 36, No. 4	
X	A46	BURKE, et al. <u>J. Med. Chem.</u> , 36:425-432 (1993).	
X	A47	CAPECCHI, "Altering the Genome by Homologous Recombination," <u>Science</u> , 1989, pp. 1288-1292, Vol. 244	
X	A48	CAPECCHI, "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," <u>Cell</u> , 1980, pp. 479-488, Vol. 22	
✓	A49	CHAN et al., "Isolation and Characterization of Chromosome - Gain and Increase - in - Ploidy Mutants in Yeast," <u>Genetics</u> , 1993, pp. 677-691, Vol. 135	
✓	A50	CHARD, <u>An Introduction to Radioimmunoassay and Related Techniques</u> , 1986, Elsevier Science Publishers, Amsterdam, The Netherlands	
✓	A51	CHATER et al., <u>Sixth International Symposium on Actinomycetales Biology</u> , 1986, pp. 45-54, Akademiai Kiado, Budapest, Hungary	
✓	A52	CHEN, "High-Efficiency Transformation of Mammalian Cells by Plasmid DNA," <u>Molecular and Cellular Biology</u> , 1987, pp. 2745-2754, Vol. 7, No. 8	
✓	A53	CHOMCZYNSKI et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," <u>Analytical Biochemistry</u> , 1987, pp. 156-159, Vol. 162	
✓	A54	CHU et al., "Electroporation for the efficient transfection of mammalian cells with DNA," <u>Nucleic Acids Research</u> , 1987, pp. 1311-1326, Vol. 15	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/734,126
		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
		<b>Attorney Docket Number</b>	034536-0928
(use as many sheets as necessary)			
Sheet	5	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
✓	A55	COURJAL et al., "DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours," <u>British Journal of Cancer</u> , 1996, pp. 1984-1989, Vol. 74	
✓	A56	COWLEY et al., "Activation of MAP Kinase Kinase is Necessary and Sufficient for PC12 Differentiation and for Transformation of NIH 3T3 Cells," <u>Cell</u> , 1994, pp. 841-852, Vol. 77	
✓	A57	CURIEL et al., "Gene Transfer to Respiratory Epithelial Cells via the Receptor-mediated Endocytosis Pathway," <u>Am. J. Respir. Cell. Mol. Biol.</u> , 1992, pp. 247-252, Vol. 6	
✓	A58	CURTIN et al., "Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717," <u>Br. J. Cancer</u> , 1986, pp. 361-368, Vol. 53	
✓	A59	DOLLE et al., "5,7-Dimethoxy-3-(4-pyridinyl)auinoline is a Potent and Selective Inhibitor of Human Vascular - Type Platelet - Derived Growth Factor Receptor Tyrosine Kinase," <u>J. Med. Chem.</u> , 1994, pp. 2627-2629, Vol. 37	
✓	A60	DONG et al., "Protein Tyrosine Kinase Inhibitors Decrease Induction of Nitric Oxide Synthase Activity in Lipopolysaccharide-Responsive and Lipopolysaccharide-Nonresponsive Murine Macrophages," <u>The Journal of Immunology</u> 151(5):2717-2724 (1993).	
✓	A61	DONG et al., "Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein - tyrosine kinase activity," <u>Journal of Leukocyte Biology</u> , 1993, pp. 53-60, Vol. 53	
✓	A62	ELLEDGE, "Cell Cycle Checkpoints: Preventing an Identity Crisis," <u>Science</u> 274:1664-1672 (1996).	
✓	A63	ENGVAL and PERLMANN, "Enzyme-Linked Immunosorbent Assay, ELISA. III. Quantitation of Specific Antibodies by Enzyme-Labeled Anti-Immunoglobulin in Antigen-Coated Tubes," <u>J. Immunology</u> 109:129-135 (1972) (mistakenly referred to as Engval).	
✓	A64	FELGNER and RINGOLD, "Cationic liposome-mediated transfection," <u>Nature</u> 337:387-388 (1989).	
✓	A65	FELGNER et al., "Lipofection: A Highly Efficient, Lipid-mediated DNA-transfection Procedure," <u>Proc. Natl. Acad. Sci. USA</u> 84:7413-7417 (1987).	
✓	A66	FERNANDES et al., "Biochemical and Antitumor Effects of 5,8-Dideazaisopteroylglutamate, a Unique Quinazoline Inhibitor of Thymidylate Synthase," <u>Cancer Research</u> 43:1117-1123 (1983).	
✓	A67	FERRIS et al., "Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <u>J. Org. Chem.</u> 44(2):173-178 (1979).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/734,126
(use as many sheets as necessary)		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	6	of	14
		<b>Attorney Docket Number</b>	034536-0928

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A68	FRANCISCO et al., "Type 1 Protein Phosphatase Acts in Opposition to IPI1 Protein Kinase in Regulating Yeast Chromosome Segregation," <u>Molecular and Cellular Biology</u> 14(7):4731-4740 (1994).	
X	A69	FRY et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," <u>Science</u> 265:1093-1095 (1994).	
X	A70	GAZIT et al., "Tyrphostins 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Med. Chem.</u> 32:2344-2352 (1989).	
X	A71	GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a -Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins," <u>J. Med. Chem.</u> 36:3556-3564 (1993).	
X	A72	GILMAN et al., "Isolation of sigma-28-specific promoters from Bacillus subtilis DNA," <u>Gene</u> 32:11-20 (1984).	
X	A73	GLICK and WHITNEY, "Factors affecting the expression of foreign proteins in Escherichia coli," <u>Journal of Industrial Microbiology</u> 1:277-282 (1987).	
X	A74	GLOVER et al., "Mutations in aurora Prevent Centrosome Separation Leading to the Formation of Monopolar Spindles," <u>Cell</u> 81:95-105 (1995).	
X	A75	GODING, "Conjugation of Antibodies with Fluorochromes: Modifications to the Standard Methods," <u>J. Immunological Methods</u> 13:215-226 (1976).	
X	A76	GOLD et al., "Translational Initiation in Prokaryotes," <u>Ann. Rev. Microbiol.</u> 35:365-403 (1981).	
X	A77	GOPALAN et al., "A Novel Mammalian, Mitotic-Spindle-associated Kinase is Related to Yeast and Fly Chromosome Segregation Regulators," <u>J. Cell. Biol.</u> 138:643-656 (1997).	
X	A78	GOTTESMAN, "Bacterial Regulation: Global Regulatory networks," <u>Ann. Rev. Genet.</u> 18:415-441 (1984).	
X	A79	GRYZAN, "Ch. 10--Molecular Cloning in Bacillus subtilis," in <u>The Molecular Biology of the Bacilli</u> , edited by Dubnau, Academic Press, New York, pp. 307-329 (1982).	
X	A80	HAMMER and WALLING, "Regulation In Vivo of a Cloned Mammalian Gene: Cadmium Induces the Transcription of a Mouse Metallothionein Gene in SV40 Vectors," <u>J. of Molecular and Applied Genetics</u> 1:273-288 (1982).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/734,126
		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-0928
Sheet	7	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A81	HAMMER et al., "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human B2m: An Animal Model of HLA-B27-Associated Human Disorders," <u>Cell</u> 63:1099-1112 (1990).	
X	A82	HARTWELL and KASTAN, "Cell Cycle Control and Cancer," <u>Science</u> 266:1821-1828 (1994).	
X	A83	HOUEBINE and CHOURROUT, "Trangensis in Fish," <u>Experientia</u> 47:891-897 (1991).	
X	A84	HUNTER, "Oncoprotein Networks," <u>Cell</u> 88:333-346 (1997).	
X	A85	HURBY et al., "Application of Synthetic Peptides: Antisense Peptides," in <u>Synthetic Peptides, A User's Guide</u> , W.H. Freeman, NY pp. 289-307 (1992), Grant G. (ed.).	
X	A86	INNIS et al., <u>PCR Protocols: A Guide to Methods and Applications</u> , edited by Michael A. Innis et al., Academic Press, San Diego (1990) (Table of Contents Only).	
X	A87	ISOLA et al., "Genetic Aberrations Detected by Comparative Genomic Hybridization Predict Outcome in Node-Negative Breast Cancer," <u>American Journal of Pathology</u> 147:905-911 (1995).	
X	A88	IWABUCHI et al., "Genetic Analysis of Benign, Low-Grade, and High Grade Ovarian Tumors," <u>Cancer Research</u> 55:6172-6180 (1995).	
X	A89	IZAKI, <u>Japanese Journal of Bacteriology</u> 33(6):729-742 (1978).	
X	A90	JACKMAN, "ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of L1210 Tumor Cell Growth in Vitro and in Vivo: A New Agent for Clinical Study," <u>Cancer Research</u> 51:5579-5586 (1991).	
X	A91	JAKOBY and WILCHEK (editors), <u>Affinity Techniques: Enzyme Purification: Part B, Methods in Enzymology</u> , Vol. XXXIV, Academic Press, New York (1974) (Table of Contents Only).	
X	A92	JAMES et al., "Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma," <u>Oncogene</u> 14:1059-1065 (1997).	
X	A93	JASNY, "Insect Viruses Invade Biotechnology," <u>Science</u> 238:1653 (1987).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/734,126
(use as many sheets as necessary)		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	8	of	14
		<b>Attorney Docket Number</b>	034536-0928

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
✓	A94	JOHN and TWITTY, "Plasmids as Epidemiologic Markers in Nosocomial Gram-Negative Bacilli: Experience at a University and Review of the Literature," <u>Reviews of Infectious Diseases</u> 8:693-704 (1986).	
✓	A95	JOHNSTON and HOPPER, "Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon," <u>Proc. Natl. Acad. Sci. USA</u> 79:6971-6975 (1982).	
✓	A96	JONES et al., "Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the Amino Acid," <u>J. Med. Chem.</u> 29:1114-1118 (1986).	
✓	A97	JOYNER et al., "Production of a mutation in mouse En-2 gene by homologous recombination in embryonic stem cells," <u>Nature</u> 338:153-156 (1989).	
✓	A98	KALLIONIEMI et al., "Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization," <u>Proc. Natl. Acad. Sci. USA</u> 91:2156-2160 (1994).	
✓	A99	KASPRZAK et al., "Location of a Contact Site Between Actin and Myosin in the Three-Dimensional Structure of the Acto-S1 Complex," <u>Biochemistry</u> 28:9230-9238 (1989) (also referred to as Kaspczak).	
✓	A100	KAUR, "Tyrophostin induced growth inhibition: correlation with effect on p210.sup.bcr-abl autokinase activity in K562 chronic myelogenous leukemia," <u>Anti-Cancer Drugs</u> 5:213-222 (1994).	
✓	A101	KENDALL and COHEN, "Plasmid Transfer in Streptomyces lividans: Identification of a kil-kor System Associated with the Transfer Region of PIJ101," <u>Journal of Bacteriology</u> 169:4177-4183 (1987).	
✓	A102	KIMURA et al., "Cell Cycle-dependent Expression and Spindle Pole Localization of a Novel Human Protein Kinase, Aik, Related to Aurora of Drosophila and Yeast Ip11," <u>J. Biol. Chem.</u> 272:13766-13771 (1997).	
✓	A103	KIMURA et al., "Molecular cloning of a human homolog of Aurora, a serine/threonine kinase which regulates the chromosome segregation," <u>Nippon Bunshi Seibutsu Gakkai Nenkai Puroguramu</u> , vol. 18, pp. 497, Abst. 3P-205 (1995).	
✓	A104	KING et al., "Site-specific dephosphorylation and deactivation of the human insulin receptor tyrosine kinase by particulate and soluble phosphotyrosyl protein phosphatases," <u>Biochem. J.</u> 275:413-418 (1991).	
✓	A105	KINZLER and VOGELSTEIN, "Cancer-susceptibility Genes: Gatekeepers and caretakers," <u>Nature</u> 386:761-763 (1997).	
✓	A106	KOHLER and MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		Application Number	10/734,126
(use as many sheets as necessary)		Filing Date	December 15, 2003
		First Named Inventor	Gregory Plowman
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	9	of	14
		Attorney Docket Number	034536-0928

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A107	KUO et al., "Effects of signalling transduction modulators on the transformed phenotypes in v-H-ras-transformed NIH 3T3 cells," <u>Cancer Letters</u> 74:197-202 (1993).	
X	A108	LARRAMENDY et al., "Gains, Losses, and Amplifications of DNA Sequences Evaluated by Comparative Genomic Hybridization in Chondrosarcomas," <u>American Journal of Pathology</u> 150:685-691 (1997).	
X	A109	LEE and SKIBO, "Active-Site-Directed Reductive Alkylation of Xanthine Oxidase by Imidazo[4,5-g]quinazoline-4,9-diones Functionalized with a Leaving Group," <u>Biochemistry</u> 26:7355-7362 (1987).	
X	A110	LEMUS et al., "Studies of Extended Quinone Methides. Synthesis and Physical Studies of Purine-like Monofunctional and Bifunctional Imidazo[4,5-g]quinazoline Reductive Alkylating Agents," <u>J. Org. Chem.</u> 54:3611-3618 (1989).	
X	A111	LEVITZKI, "Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction," <u>FASEB J.</u> 6:3275-3282 (1992).	
X	A112	LEY and SENG, "Synthesis Using Benzofuroxan," <u>Synthesis</u> 1975:415-422 (1975).	
X	A113	LUI et al., "Construction of a GAL1-Regulated Yeast cDNA Expression Library and its Application to the Identification of Genes Whose Overexpression Causes Lethality in Yeast," <u>Genetics</u> 132:665-673 (1992).	
X	A114	LUTZ et al., "The Distribution of Two hnRNP-Associated Proteins Defined by a Monoclonal Antibody Is Altered in Heat-Shocked HeLa Cells," <u>Experimental Cell Research</u> 175:109-124 (1988).	
X	A115	LYALL et al., "Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," <u>J. Biol. Chem.</u> 264:14503-14509 (1989).	
X	A116	MALONE et al., <u>Focus</u> 11:66 (1989).	
X	A117	MANIATIS, In: <u>Cell Biology: A Comprehensive Treatise</u> , vol. 3, <u>Gene Sequence Expression</u> , Academic Press, NY, pp. 563-608 (1980).	
X	A118	MARKOWITZ et al., "Construction and Use of a Safe and Efficient Amphotropic Packaging Cell Line," <u>Virology</u> 167:400-406 (1988).	
X	A119	MAXWELL et al., ".sup.19 F Nuclear Magnetic Resonance Imaging of Drug Distribution in Vivo: The Disposition of an Antifolate Anticancer Drug in Mice," <u>Magnetic Resonance in Medicine</u> 17:189-196 (1991).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/734,126
				Filing Date	December 15, 2003
				First Named Inventor	Gregory Plowman
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	10	of	14	Attorney Docket Number	034536-0928

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
✓	A120	McKNIGHT, "Functional Relationships between Transcriptional Control Signals of the Thymidine Kinase Gene of Herpes Simplex Virus," <u>Cell</u> 31:355-365 (1992).		
✓	A121	MILLER and ROSMAN, "Improved Retroviral Vectors for Gene Transfer and Expression," <u>BioTechniques</u> 7(9):980-990 (1989).		
✓	A122	MILLER et al., In: <u>Genetic Engineering</u> , Vol. 8, Plenum, Setlow et al., eds., pp. 277-297 (1986).		
✓	A123	MILLER, "Human gene therapy comes of age," <u>Nature</u> 357:455-460 (1992).		
✓	A124	MINI et al., "Cytotoxic Effects of Folate Antagonists against Methotrexate-resistant Human Leukemic Lymphoblast CCRF-CEM Cell Lines," <u>Cancer Research</u> 45:325-330 (1985).		
✓	A125	MITELMAN et al, <u>Nature Genet.</u> , 15:417-474 (1997).		
✓	A126	MOSSIE al., "Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family," <u>Oncogene</u> 11(10):2179-2184 (1995).		
✓	A127	MULERIS et al., "Characteristic Chromosomal Imbalances in 18 Near-Diploid Colorectal Tumors," <u>Cancer Genet Cytogenet</u> 29:289-301 (1987).		
✓	A128	MULLIGAN, "The Basic Science of Gene Therapy," <u>Science</u> 260-926-932 (1993).		
✓	A129	NELSON, "Detection of Acridinium Esters by Chemiluminescence," <u>Nonisotopic DNA Probe Techniques</u> , ed. Larry J. Kricka, (San Diego:Academy Press, Inc.) pp. 275-310 (1992) (Table of Contents Only).		
✓	A130	OKAYAMA and BERG, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <u>Molecular and Cellular Biology</u> 3:280-289 (1983).		
✓	A131	PATI, "Novel vectors for expression of cDNA encoding epitope-tagged proteins in mammalian cells," <u>Gene</u> 114:2856-288 (1992).		
✓	A132	PETERSON and BARNES, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <u>The Prostate</u> 22:335-345 (1993).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/734,126 December 15, 2003 Gregory Plowman Unassigned Unassigned 034536-0928
Sheet	11	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A133	PHILLIPS and CASTLE, "Quino[1,2-c]quinazolines. I. Synthesis of Quino[1,2-c]quinazolinium Derivatives and the Related Indazolo[2,3-a]quinoline Derivatives as Analogs of the Antitumor Benzo[c]phenanthridine Alkaloids," <u>J. Heterocyclic Chemistry</u> 17:1489-1496 (1980).	
X	A134	PILLEMER et al., "Insulin Dependence of Murine Lymphoid T-Cell Leukemia," <u>Brit. J. Cancer</u> 50:80-85 (1992).	
X	A135	POSNER et al., "Kinetics of inhibition by Tyrphostins of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor and Analysis by a New Computer Program," <u>Molecular Pharmacology</u> 45:673-683 (1993).	
X	A136	PURSEL et al., "Genetic Engineering of Livestock," <u>Science</u> 244:1281-1288 (1989).	
X	A137	REDEMANN et al., "Anti-Oncogenic Activity of Signalling-Defective Epidermal Growth Factor Receptor Mutants," <u>Molecular and Cellular Biology</u> 12(2):491-498 (1992).	
X	A138	REECE et al., "Pharmacokinetics of Trimetrexate Administered by Five-Day Continuous Infusion to Patients with Advanced Cancer," <u>Cancer Research</u> 47:2996-2999 (1987).	
X	A139	RENDU et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," <u>Biochemical Pharmacology</u> 44(5):881-888 (1992).	
X	A140	REZNIKOFF et al., "A Molecular Genetic Model of Human Bladder Cancer Pathogenesis," <u>Seminars in Oncology</u> 23:571-584 (1996).	
X	A141	ROBERTSON, E.J., ed., <u>Teratocarcinomas and Embryonic Stem Cells, A Practical Approach</u> , IRL Press (1987).	
X	A142	ROGHI et al., "Xenopus laevis mRNA encoding protein kinase," <u>EMBL Sequence Database</u> , Heidelberg, Brd., XP002029130, accession No. Z17206, Jan. 1, 1995.	
X	A143	ROGHI et al., "Xenopus laevis mRNA encoding protein kinase," <u>EMBL Sequence Database</u> , Heidelberg, Brd., XP002029131, accession No. Z17207, Jan. 1, 1995.	
X	A144	RUBIN, "Drosophila melanogaster as an Experimental Organism," <u>Science</u> 240:1453-1459 (1988).	
X	A145	SAMBROOK, FRITSCH & MANIATIS, eds., <u>Molecular Cloning: A Laboratory Manual</u> , second edition, Cold Spring Harbor Laboratory (1989).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/734,126
		<b>Filing Date</b>	December 15, 2003
		<b>First Named Inventor</b>	Gregory Plowman
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	034536-0928
Sheet	12	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A146	SAURO and THOMAS, "Decreased Sensitivity of Aorta from Hypertensive Rats to Vasorelaxation by Tyrphostin," <u>Life Sciences</u> 53:PL371-376 (1993).	
✓	A147	SAURO and THOMAS, "Tyrphostin Attenuates Platelet-Derived Growth Factor-Induced Contraction in Aortic Smooth Muscle Through Inhibition of Protein Tyrosine Kinase(s)," <u>The Journal of Pharmacology and Experimental Therapeutics</u> 267:1119-1125 (1993).	
X	A148	SAVELIEVA et al., "20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells," <u>Oncogene</u> 14:551-560 (1997).	
✓	A149	SCHLEGEL et al., "Comparative Genomic in Situ Hybridization of Colon Carcinomas with Replication Error," <u>Cancer Research</u> 55:6002-6005 (1995).	
✓	A150	SCULIER et al., "Role of an Intensive Care Unit (ICU) in a Medical Oncology Department," <u>Cancer Immunol. and Immunotherapy</u> 23:A65 at abstract No. 257 (1986).	
✓	A151	SEN et al., "A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines," <u>Oncogene</u> 14:2195-2200 (1997)	
✓	A152	SHERR, "Cancer Cell Cycles," <u>Science</u> 274:1672-1677 (1996).	
✓	A153	SIKORA and GRZELAKOWSKA-SZTABERT, "Quinazoline CB 3717 and CB 3703 Inhibitors of Folate Retention and Metabolism in Ehrlich Ascites Carcinoma Cells and Some Organs of the Host-Mouse," <u>Cancer Letters</u> 23:289-295 (1984).	
✓	A154	SIKORA et al., "Development of an Assay for the Estimation of N.sup.10 -Propargyl-5,8-dideazafolic Acid Polyglutamates in Tumor Cells," <u>Analytical Biochemistry</u> 172:344-355 (1988).	
✓	A155	SILVER et al., "Amino terminus of the yeast GAL4 gene product is sufficient for nuclear localization," <u>Proc. Natl. Acad. Sci. USA</u> 81:5951-5955 (1984).	
✓	A156	SIMONS et al., "Gene Transfer into Sheep," <u>Bio/Technology</u> 6:179-182 (1988) (also referred to as Simms or Simmons).	
✓	A157	SOLINAS-TOLDO et al., "Mapping of Chromosomal Imbalances in Pancreatic Carcinoma by Comparative Genomic Hybridization," <u>Cancer Research</u> 56:3803-3807 (1996).	
✓	A158	SOUTHERN, "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis," <u>J. Mol. Biol.</u> 98:503-517 (1975).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/734,126 December 15, 2003 Gregory Plowman Unassigned Unassigned 034536-0928
Sheet	13	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
X	A159	ST. GROTH and SCHEIDEGGER, "Production of Monoclonal Antibodies: Strategy and Tactics," <u>J. Immunol. Methods</u> 35:1-21 (1980).	
X	A160	STERNBERGER et al., "The Unlabeled Antibody Enzyme Method of Immunohistochemistry: Preparation and Properties of Soluble Antigen-Antibody Complex (Horseradish Peroxidase-Antihorseradish Peroxidase) and Its Use in Identification of Spirochetes," <u>J. Histochemistry and Cytochemistry</u> 18(5):315-333 (1970) (mistakenly referred to as Stemberger).	
X	A161	TABOR et al., "DNA sequence analysis with a modified bacteriophage T7 DNA polymerase," <u>Proc. Natl. Acad. Sci. USA</u> 84:4767-4771 (1987).	
X	A162	TANNER et al., "Increased Copy Number at 20q13 in Breast Cancer: Defining the Critical Region and Exclusion of Candidate Genes," <u>Cancer Research</u> 54:4257-4260 (1994).	
X	A163	TANNER et al., "Independent Amplification and Frequent Co-Amplification of Three Nonsyntenic Regions on the Long Arm of Chromosome 20 in Human Breast Cancer," <u>Cancer Research</u> 56:3441-3445 (1996).	
X	A164	TIJSEN, "Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology," Elsevier Science Publishers, Amsterdam, The Netherlands (1985).	
Y	A165	TIRKKONENE et al., "Distinct Somatic Genetic Changes Associated with Tumor Progression in Carriers of BRCA1 and BRCA2 Germ-line Mutations," <u>Cancer Research</u> 57:1222-1227 (1997)	
Y	A166	TUNG et al., <u>Molecular and cellular Biology</u> , 15(11), 6064-6074, Nov. 1995.	
X	A167	ULMANEN et al., "Transcription and Translation of Foreign Genes in Bacillus subtilis by the Aid of a Secretion Vector," <u>Journal of Bacteriology</u> 162:176-182 (1985).	
X	A168	WARD et al., "Construction and characterisation of a series of multi-copy promoter-probe plasmid vectors for Streptomyces using the aminoglycoside phosphotransferase gene from Tn5 as indicator," <u>Mol. Gen. Genet.</u> 203:468-478 (1986).	
X	A169	WEIR (eds), "Ch. 10--The chemistry and standardization of allergens," in <u>Handbook of Experimental Immunology--Volume 1: Immunochemistry</u> , 4th Ed., edited by Weir et al., Blackwell Scientific Publications, Oxford, England, pp. 10.1-10.28 (1986).	
Y	A170	WOLBRING et al., "Inhibition of GTP-utilizing Enzymes by Tyrphostins," <u>J. Biol. Chem.</u> 269:22470-22472 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

**Complete if Known**

Sheet	14	of	14
-------	----	----	----

[illegible]Date  
Considered

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

i did not receive